Kobayashi Pharmaceutical Co., Ltd. plans to propose amendments to its articles of incorporation at the 108th Annual General Meeting of Shareholders scheduled for March 27, 2026, to transition to a company with an audit and supervisory committee, aiming to strengthen the board of directors’ supervisory functions and improve management agility.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4967","jir_company_name":"Kobayashi Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-18","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4967-20260218-01.pdf","jir_short_summary":"Kobayashi Pharmaceutical Co., Ltd. plans to propose amendments to its articles of incorporation at the 108th Annual General Meeting of Shareholders scheduled for March 27, 2026, to transition to a company with an audit and supervisory committee, aiming to strengthen the board of directors' supervisory functions and improve management agility.","jir_summary":"### Purpose and Overview of Amendments to the Articles of Incorporation\nKobayashi Pharmaceutical Co., Ltd. is promoting a fundamental reform of corporate governance as part of measures to prevent recurrence of issues involving unexpected components found in some ingredients of red yeast rice related products. As part of this, the company has decided to transition to a company with an audit and supervisory committee and will partially amend its articles of incorporation to strengthen the supervisory functions of the board of directors and expedite management. Major changes include the deletion of provisions related to auditors and the audit committee and the establishment of new provisions regarding audit and supervisory committee members and the audit and supervisory committee, categorization of the appointment and term of directors, and revision of the resolution methods of the board of directors.\n\n### Future Schedule and Shareholders Meeting Agenda\nThese amendments to the articles of incorporation will be submitted for approval at the 108th Annual General Meeting of Shareholders to be held on March 27, 2026, and will take effect from that same day. The shareholders meeting will include the election of three directors who are audit and supervisory committee members and seven directors who are not, determination of remuneration amounts for each director, and will also deliberate on four shareholder proposals. Through this, the board of directors aims to further strengthen its supervisory function over management while enhancing the speed and agility of decision-making.","jir_financial_highlights":"Effective Date of Articles of Incorporation Amendment: 2026-03-27 (Unknown)\nNumber of Directors: Up to 10 (of which up to 5 are directors who are Audit and Supervisory Committee members) (New Regulation)\nTerm of Office for Directors Who Are Audit and Supervisory Committee Members: Until the conclusion of the ordinary general meeting of shareholders for the business year ending within two years after appointment (New Regulation)","jir_category":"","jir_hashtags":"#KobayashiPharmaceutical, #CorporateRestructuring, #CompanyWithAuditAndSupervisoryCommittee","jir_key_figures":"Effective Date of Articles of Incorporation Amendment: 2026-03-27\nNumber of Directors: Up to 10 (of which up to 5 are directors who are Audit and Supervisory Committee members)\nTerm of Office for Directors Who Are Audit and Supervisory Committee Members: Until the conclusion of the ordinary general meeting of shareholders for the business year ending within two years after appointment","jir_meta_title":"Kobayashi Pharmaceutical Co., Ltd. to Implement Articles of Incorporation Amendments Due to Transition to a Company with an Audit and Supervisory Committee on March 27, 2026","jir_meta_description":"Kobayashi Pharmaceutical Co., Ltd. will partially amend its articles of incorporation on March 27, 2026, in conjunction with its transition to a company with an audit and supervisory committee, aiming to strengthen board supervisory functions and expedite management.","jir_og_title":"Kobayashi Pharmaceutical Announces Transition to a Company with an Audit and Supervisory Committee","jir_og_description":"Kobayashi Pharmaceutical Co., Ltd. will transition to a company with an audit and supervisory committee effective March 27, 2026, implementing amendments to its articles of incorporation to enhance its management structure.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7982,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-29989","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n